Fentanyl has high aff inity for theμ-opioid receptor, and its analgesic effect is 70 to 100 times more potent than that of morphine 1) . The high lipid solubility and low molecular weight of fentanyl make it suitable for transdermal administration. The bioavailability of transdermally administered fentanyl has been reported to be 92% 2) . In 2002, a transdermal therapeutic system (TTS) for fentanyl incorporating reservoir technology was first marketed as the Durotep®Patch in Japan. The reservoir patch has a gel reservoir containing fentanyl and is available in 4 different sizes, with fentanyl release rates of 25, 50, 75, and 100μg/h (containing 2.5, 5.0, 7.5, and 10 mg fentanyl per patch, respectively). Replacement of the reservoir patch is only required every 72 h after application; moreover, it is useful in patients with dysphasia.
Introduction

Influence of body fat in cancer patients on residual content of used fentanyl matrix patches
Takeshi Chiba 1) , Yusuke Kimura 2) , Hiroaki Takahashi 3) , Tomohiko Tairabune 3) , Yoshiaki Nagasawa 3) , Kaoru Mori 3) , Yuji Yonezawa 3) , Atsuko Sugawara 4) , Sachiko Kawaguchi 3) , Hidenobu Kawamura 5) , Satoshi Nishizuka 2) , Kenzo Kudo 1, 3) , Kunihiko Fujiwara 1) , Kenichiro Ikeda 2) fentanyl content of used reservoir patches 8, 9) , suggesting that these factors may affect the transdermal absorption of fentanyl in reservoir patches. In a clinical study of patients experiencing cancer-related pain with or without cachexia using the reservoir patch, transdermal fentanyl absorption was impaired in the cachectic patients (mean BMI, 16 kg/m 2 versus 23 kg/m 2 ) 10) . As BMI is a measure of obesity, the body fat level in cancer patients may affect the skin permeability of fentanyl. No previous studies have focused on the correlation between body fat level and transdermal fentanyl absorption. To evaluate the degree of body fat in cancer patients, we measured body fat rate (BFR) and triceps skinfold thickness (TSF). The aim of this study was to determine whether these parameters are associated with estimated transdermal absorption of fentanyl in the matrix patch, in patients treated for moderate to severe cancer pain, by measuring the residual content of fentanyl in the used matrix patches.
Materials and methods 1 Patients
Adult Japanese inpatients experiencing chronic cancer-related pain and undergoing treatment for the first time with a transdermal fentanyl matrix patch (Durotep®MT patch, Janssen-Pharma, Japan)
were included in the present study. The patients were provided with verbal and written information about the study, and then gave their written informed consent. The dose of the patch selected for each patient was based on clinical considerations. Exclusion criteria included the following: impaired cognitive function; fever (≧38 ℃);
pregnancy; lactation; clinically significant renal, hepatic, or cardiac insufficiency; skin disease precluding the use of a fentanyl patch;
and previous use of either the matrix or the reservoir patch. At the time of patch application and removal, the absent of abnormal findings (e.g. skin separation) was visually confirmed for each patient. Before applying the patch, patients were visually checked to ensure that the application site of the patch had no contamination.
The patients were interviewed about the presence or absence of sweating during the study period. This study protocol was reviewed and approved by the Iwate Medical University Ethics Committee.
Method of application and removal of the patch
Application and removal of the patch were performed by nurses.
The application site was the chest or upper arm. One used patch was collected from each patient. After removal from each patient, the patches were wrapped in Saran Wrap®(Asahi Kasei, Japan) and then stored at 4 ℃ until analysis.
Measurement of parameters
During the initial application period, body weight (BW), body height (BH), BFR, and TSF were measured. To preclude any error in measurement, TSF was measured by an experienced nurse using an adipometer (Abbott Japan Co. Ltd., Japan). BFR was measured . The flow rate and detection wavelength were 1.5 ml/min and 271 nm, respectively. Fentanyl injection (50μg/ml; Daiichi-Sankyo, Japan) was used as a standard solution. Ethyl p-hydroxybenzoic acid (25μg/ml, Wako Pure Chemical Industries Ltd., Japan) was prepared in methanol and used as an internal standard.
Sample preparation
Each patch was cut in half with scissors and then placed in a vial containing 40 ml 0.1% phosphoric acid/acetonitrile solution ( Three used patches removed from 4 patients were also tested, and similar dissolution profiles were observed (data not shown).
Estimation of the transdermal delivery efficacy of the patch
The rate (measured inμg/h) of effective transdermal fentanyl delivery and the transdermal delivery efficiency (measured in %)
were estimated as described by Van Nimmen et al. The delivery efficiency (%) was determined using the following equation:
Delivery efficiency (%)＝ 〔estimated dose rate ( μg/h) / nominal dose rate ( μg/h)〕 ×100 showed a significant positive correlation with delivery efficiency.
Scatter graphs of these correlations are presented in Fig. 1 . In addition, BMI also showed a significant positive correlation with delivery efficiency (data not shown).
Discussion
Yamamoto et al. estimated the dose transfer rate by measuring the residual content of fentanyl in the used reservoir patch and reported that BMI in cancer patients was inversely correlated with estimated fentanyl transfer rate. Furthermore, they suggested that the decrease in the transfer rate in obese patients was due to suppression of passive diffusion of fentanyl from the patch to the skin, which in turn led to accumulation of fentanyl in the subcutaneous fat layer 9) .
However, only 4 patients were included their study, and BMI was the only index of fat level. As the blood concentration of fentanyl of in low-BMI (mean 16 kg/m 2 ) in cancer patients is significantly lower than that of normal-BMI patients (mean 23 kg/m 2 ) 10) , it remains controversial whether or not body fat in cancer patients reduces transdermal fentanyl absorption. Therefore, it is necessary to evaluate body fat in detail, and to include more cancer patients.
In the present study, we included 15 patients, and measured BFR and TSF as indices of fat level. Furthermore, we investigated the effect of both measurements on the residual content of fentanyl in the used matrix patches. As prior experience with the reservoir patches and matrix patches might influence our results, only patients who had never used either patch were included in this study. To rule out factors that may have influence the estimated transdermal fentanyl absorption, patients presenting sweating, skin contamination, or fever (≧38 ℃) during the initial application period were excluded from this study. As differences in the methods of application and removal of patch could influence our results, they were standardized before the start of the study. In our investigation, Most advanced cancer patients have malnutrition with anorexia, weight loss, decrease in body fat and muscle, dehydration, and electrolyte abnormalities 12, 13) . In addition, dry skin is a common physical sign in advanced cancer patients with malnutrition 14) . It is possible that patients with low-body fat in this study may have had malnutrition.
Although some reports concerning the relationship between transdermal fentanyl absorption and body fat (or BMI) have been published, it remains controversial. Our results may be attributable to dry skin cause by malnutrition. In malnourished or low-body fat patients receiving DMP, pain intensity should be more carefully monitored, and fentanyl dose adjustment may be required.
However, this study was conducted on a small scale, thus limiting the evaluation of transdermal fentanyl absorption, skin condition, and nutritional status in cancer patients. A detailed evaluation of additional parameters, such as the degree of dry skin measured by transdermal epidermal water loss and nutritional status including body fat change, in cancer patients is required. Furthermore, the effect of parameters on plasma fentanyl concentration should be explored.
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